Display options
Cite
MacKichan JJ. Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clin Pharmacokinet. 1984;9:32-41doi: 10.2165/00003088-198400091-00005.
MacKichan, J. J. (1984). Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clinical pharmacokinetics, 932-41. https://doi.org/10.2165/00003088-198400091-00005
MacKichan, J J. "Pharmacokinetic consequences of drug displacement from blood and tissue proteins." Clinical pharmacokinetics vol. 9 (1984): 32-41. doi: https://doi.org/10.2165/00003088-198400091-00005
MacKichan JJ. Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clin Pharmacokinet. 1984 Jan;9:32-41. doi: 10.2165/00003088-198400091-00005. PMID: 6705425.
Copy Download .nbib Format: NLM
Share it on
Full text links
Springer

Clin Pharmacokinet. 1984 Jan;9:32-41. doi: 10.2165/00003088-198400091-00005.

Pharmacokinetic consequences of drug displacement from blood and tissue proteins.

Clinical pharmacokinetics

J J MacKichan

PMID: 6705425 DOI: 10.2165/00003088-198400091-00005

Abstract

Displacement of one drug by another from blood and/or tissue protein will alter the pharmacokinetic behaviour of the displaced drug. For restrictively cleared drugs, displacement from blood proteins will cause only a transient change in free drug concentration and hence in pharmacodynamic response, so that dosage adjustments are rarely necessary. Total drug concentrations, however, are decreased and must be appropriately interpreted. Binding displacement from blood and/or tissue will also shorten the half-lives of these drugs, thus magnifying peak-trough differences during a dosage interval. These theoretical expectations are supported by examples of drug displacement interactions involving warfarin and phenytoin. Although total drug concentrations in blood will be unchanged, free drug concentrations will be increased and drug response enhanced for non-restrictively cleared drugs as a result of displacement from blood protein, possibly necessitating a dosage reduction.

References

  1. Life Sci. 1976 Jul 1;19(1):125-30 - PubMed
  2. Clin Pharmacol Ther. 1981 Jan;29(1):56-60 - PubMed
  3. Clin Pharmacol Ther. 1980 Dec;28(6):779-89 - PubMed
  4. Clin Pharmacol Ther. 1976 May;19(5 Pt 1):552-8 - PubMed
  5. Clin Pharmacol Ther. 1972 Nov-Dec;13(6):911-5 - PubMed
  6. Ann N Y Acad Sci. 1971 Jul 6;179:43-66 - PubMed
  7. Clin Chem. 1979 Jun;25(6):856-9 - PubMed
  8. Clin Pharmacol Ther. 1980 Feb;27(2):170-8 - PubMed
  9. Clin Pharmacol Ther. 1978 Jul;24(1):1-4 - PubMed
  10. N Engl J Med. 1970 Oct 15;283(16):827-31 - PubMed
  11. Ann Intern Med. 1974 Sep;81(3):341-4 - PubMed
  12. Clin Pharmacol Ther. 1982 May;31(5):642-9 - PubMed
  13. Clin Pharmacol Ther. 1980 Jan;27(1):89-95 - PubMed
  14. Ann N Y Acad Sci. 1971 Jul 6;179:421-31 - PubMed
  15. Clin Pharmacol Ther. 1978 Feb;23(2):165-74 - PubMed
  16. J Pharmacol Exp Ther. 1976 Oct;199(1):67-73 - PubMed
  17. J Pharmacol Exp Ther. 1981 Dec;219(3):741-7 - PubMed
  18. Clin Pharmacol Ther. 1975 Oct;18(4):377-90 - PubMed
  19. Pharmacology. 1979;18(5):225-7 - PubMed
  20. Biochem Pharmacol. 1973 Dec 1;22(23):3099-108 - PubMed
  21. Mol Pharmacol. 1975 Nov;11(6):824-32 - PubMed
  22. Anesth Analg. 1981 Jun;60(6):395-400 - PubMed
  23. J Pharm Sci. 1970 Sep;59(9):1258-61 - PubMed
  24. Clin Pharmacokinet. 1980 May-Jun;5(3):246-62 - PubMed
  25. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):494-500 - PubMed
  26. Clin Pharmacol Ther. 1976 Aug;20(2):152-7 - PubMed
  27. J Clin Invest. 1974 Jun;53(6):1607-17 - PubMed
  28. Eur J Clin Pharmacol. 1978 Jul 30;13(5):373-80 - PubMed
  29. N Engl J Med. 1976 Feb 5;294(6):311-6 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources